1-(3-BETA-D-吡喃葡萄糖基-2,4,6-三羟基苯基)-3-(4-羟基苯基)-1-丙酮
| 中文名称 | 1-(3-BETA-D-吡喃葡萄糖基-2,4,6-三羟基苯基)-3-(4-羟基苯基)-1-丙酮 |
|---|---|
| 中文同义词 | 1-(3-BETA-D-吡喃葡萄糖基-2,4,6-三羟基苯基)-3-(4-羟基苯基)-1-丙酮;化合物NOTHOFAGIN;化合物NOTHOFAGIN,10 MM DMSO 溶液;3-(4-羟基苯基)-1-[2,4,6-三羟基-3-[(2S,3R,4R,5S,6R)-3,4,5-三羟基-6-(羟甲基)四氢-2H-吡喃-2-基]苯基]-1-丙酮;Nothofagin #天然产物 HY-113919;Nothofagin #天然产物 HY-113919 |
| 英文名称 | Nothofagin |
| 英文同义词 | Nothofagin;1-(3-beta-D-Glucopyranosyl-2,4,6-trihydroxyphenyl)-3-(4-hydroxyphenyl)-1-propanone;(1S)-1,5-Anhydro-1-{2,4,6-trihydroxy-3-[3-(4-hydroxyphenyl)propanoyl]phenyl}-D-glucitol;1-Propanone, 1-(3-β-D-glucopyranosyl-2,4,6-trihydroxyphenyl)-3-(4-hydroxyphenyl)-;3-(4-Hydroxyphenyl)-1-(2,4,6-trihydroxy-3-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)phenyl)propan-1-one;Nothofagin, 10 mM in DMSO;3-(4-Hydroxyphenyl)-1-[2,4,6-trihydroxy-3-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl]phenyl]-1-propanone |
| CAS号 | 11023-94-2 |
| 分子式 | C21H24O10 |
| 分子量 | 436.41 |
| EINECS号 | |
| 相关类别 | 对照品;分析试剂标准品 |
| Mol文件 | 11023-94-2.mol |
| 结构式 |  |
1-(3-BETA-D-吡喃葡萄糖基-2,4,6-三羟基苯基)-3-(4-羟基苯基)-1-丙酮 性质
| 储存条件 | under inert gas (nitrogen or Argon) at 2-8°C |
|---|---|
| 形态 | 固体 |
| 颜色 | 白色至米白色 |
Nothofagin pre-treatment (0.1, 1, 10 μM) decreases the level of histamine release in RBL-2H3 and RPMCs cells. The production of cytokines are downregulated bynothofagin pre-treatment Nothofagin (TNF-α: 1-10 μM; IL-4: 0.1-10 μM, IL-6: 1-10 μM).
Pre-treatment of DNPHSA-stimulated RBL-2H3 with Nothofagin (10 μM) markedly suppresses the phosphorylation of Lyn, Syk, and Akt.
Nothofagin (30 μM; for 6 hours) results in inhibited formation of LPS-induced (100 ng/mL; 4 hours) paracellular gaps with the formation of dense F-actin rings in HUVECs.
Nothofagin suppresses IgE-mediated mast cell degranulation both in vitro and in vivo.
Nothofagin (1 mg/kg; orally; once a day; for 7 days) significantly increases the urinary volume of both normotensive (NTR) and spontaneously hypertensive rats (SHR).
| Animal Model: | Male Wistar normotensive and spontaneously hypertensive rats (3-4 months old) |
| Dosage: | 1 mg/kg |
| Administration: | Orally; once a day; for 7 days |
| Result: | Significantly increased the urinary volume of both NTR and SHR. |
安全信息
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2025/12/22 | HY-113919 | 1-(3-BETA-D-吡喃葡萄糖基-2,4,6-三羟基苯基)-3-(4-羟基苯基)-1-丙酮 Nothofagin | 11023-94-2 | 1 mg | 5819元 |
| 2023/03/20 | HY-113919 | 1-(3-BETA-D-吡喃葡萄糖基-2,4,6-三羟基苯基)-3-(4-羟基苯基)-1-丙酮 Nothofagin | 11023-94-2 | 5mg | 12500元 |